Efforts to Countermeasure New Coronavirus Infection In response to the declaration of a state of emergency
January 08, 2021
Japan Pharmaceutical Manufacturers Association
Chairman Joji Nakayama
The spread of the novel coronavirus continues, and even today, many people are infected and many irreplaceable lives have been lost. Under these circumstances, I would like to express my heartfelt gratitude to all those who are doing their utmost to fight the virus and to all those who carry out essential tasks in our daily lives.
As a member of the Japan Pharmaceutical Manufacturers Association (JPMA), we, the pharmaceutical industry, are in a position to contribute to the nation's healthcare through research, development, and stable supply of pharmaceutical products. In response to the declaration of a state of emergency issued on January 7 for Tokyo, Saitama, Chiba, and Kanagawa prefectures, we are committed to further efforts and promotion of the following items related to measures against new coronavirus infection
-
Based on the recognition that the rapid research and development of safe and effective drugs and vaccines is an important means to achieve a speedy conclusion of the disease, the member companies of the Pharmaceutical Manufacturers Association of Japan (PMAJ) will continue to work diligently to deliver safe and effective drugs and vaccines for infectious diseases to those who need them.
-
In order to ensure that the treatment of all diseases is not delayed in the midst of a tight medical situation, the member companies of the Pharmaceutical Manufacturers Association of Japan (PMMA) will continue to supply necessary drugs and provide appropriate information to medical institutions and others.
-
The spread of infectious diseases has caused temporary suspensions or delays in clinical trials for new drugs needed in areas other than infectious diseases. The member companies of the Pharmaceutical Manufacturers Association of Japan (PMAJ) will continue to make their best efforts to make up for the delays in clinical trials in various therapeutic areas, while taking into consideration the burden on medical institutions and others, so that new drugs can be provided as soon as possible to patients who are eagerly awaiting them.
We, the pharmaceutical industry, will continue to work in close collaboration with government agencies and other related parties to bring the new coronavirus out of the epidemic as soon as possible and save as many lives as possible.
For inquiries regarding this matter, please contact
Japan Pharmaceutical Manufacturers Association, Public Relations Department
- Phone
- 03-3241-0374